PDL Buys Rights to Diabetes Drug Payments from Depomed

Oct 22, 2013

Huff Post Business

PDL BioPharma is buying the rights to receive royalty and milestone payments on several Type 2 diabetes treatments from Depomed in a deal valued at $240.5 million. The biggest earner in the group is Glumetza, which is marketed by Santarus Inc. PDL said Depomed received $42.8 million in royalty payments on that drug in 2012. PDL will also get payments on sales of Merck & Co.'s Janumet XR and several experimental drugs. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments